Epidemiology from Literature | Cohort | Year | Country | Test | Subjects | Positive (%) | Bibliography | 1.4 - Respiratory Symptoms, Diagnosed | 2014 | Austria | IgE | 42 | 41.000 | 20140707, Banerjee S
| 1.4 - Respiratory Symptoms, Diagnosed | 1994 | Taiwan | IgE | 100 | 40.000 | | 1.4 - Respiratory Symptoms, Diagnosed | 1994 | Taiwan | SPT | 45 | 51.000 | | 1.4 - Respiratory Symptoms, Diagnosed | 2002 | Thailand | SPT | 95 | 6.300 | | 1.4 - Respiratory Symptoms, Diagnosed | 2002 | Thailand | SPT | 85 | 7.060 | 2002, Trakultivakorn M
| 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Austria | IgE | 5 | 33.000 | 20140707, Banerjee S
| 1.5 - Atopic Dermatitis, Diagnosed | 2014 | Germany | IgE | 100 | 39.000 | 20140707, Banerjee S
| 3.1.1 - Source Sensitized (SPT) | 2003 | Malaysia | IgE | 49 | 38.800 | | 3.1.1 - Source Sensitized (SPT) | 2003 | Taiwan | IgE | 146 | 77.400 | | 3.1.1 - Source Sensitized (SPT) | 2003 | Thailand | SPT | 45 | 24.400 | | 3.1.1 - Source Sensitized (SPT) | 2003 | United Kingdom | SPT | 19 | 66.700 | | 3.2.1 - Source Sensitized (IgE) | 2003 | Austria | IgE | 20 | 15.000 | | 3.2.1 - Source Sensitized (IgE) | 2003 | United Kingdom | IgE | 19 | 31.600 | | 3.2.1 - Source Sensitized (IgE) | 2010 | United States | IgE | 62 | 35.500 | 20100610, Mueller GA
| 3.2.1 - Source Sensitized (IgE) | 2003 | Zimbabwe | IgE | 20 | 45.000 | | 4.1.3 - Heterologous Source Sensitized (SPT) | 1999 | Singapore | SPT | 46 | 19.000 | | 4.1.4 - Heterologous Source Sensitized (Symptoms, IgE) | 2008 | Sweden | IgE | 31 | 0.000 | 20081121, Weghofer M
| 5.2.1 - Source Exposed (Symptoms, SPT) | 2004 | Australia / Austria | IgE | 78 | 17.900 | | 5.2.1 - Source Exposed (Symptoms, SPT) | 1998 | Venezuela | SPT | 150 | 60.000 | | 5.2.1 - Source Exposed (Symptoms, SPT) | 1997 | Venezuela | SPT | 60 | 60.000 | | 5.2.4 - Source Exposed, Adults (Symptoms, IgE) | 2008 | Austria | IgE | 117 | 51.280 | 20080425, Weghofer M
| 5.2.5 - Source Exposed, Children (Symptoms, IgE) | 2006 | Australia | IgE | 105 | 29.500 | 20060524, Hales BJ
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2006 | Australia | IgE | 77 | 39.000 | 20060524, Hales BJ
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2008 | Austria | IgE | 56 | 46.000 | 20081121, Weghofer M
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2007 | Colombia | IgE | 90 | 37.800 | 20080220, Jimenez S
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2008 | France | IgE | 55 | 64.000 | 20081121, Weghofer M
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2008 | Italy | IgE | 67 | 43.000 | 20081121, Weghofer M
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2008 | Sweden | IgE | 65 | 23.000 | 20081121, Weghofer M
| 5.3.1 - Source Exposed (Symptoms, IgE) | 2000 | Taiwan | IgE | 248 | 35.880 | 20000606, Hu C
| 5.3.1 - Source Exposed (Symptoms, IgE) | 1997 | Venezuela | IgE | 56 | 57.000 | | 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2012 | Australia | IgE | 37 | 46.000 | 20121018, Hales BJ
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2011 | Austria | IgE | 62 | 34.590 | 20110629, Resch Y
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2012 | France | IgE | 19 | 47.360 | 20120622, Casset A
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2012 | Italy | IgE | 26 | 30.770 | 20120622, Casset A
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2011 | Singapore | IgE | 225 | 11.000 | 20110221, Kidon MI
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2010 | Singapore | IgE | 30 | 90.000 | 20100326, Shek LP
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2010 | Singapore | IgE | 30 | 66.700 | 20100326, Shek LP
| 5.4.1 - Source Exposed (Symptoms, SPT, IgE) | 2014 | Thailand | IgE | 96 | 69.000 | 20140530, Pulsawat P
|
|